Alerts will be sent to your verified email
Verify EmailPFIZER
|
Pfizer
|
Astrazeneca Pharma
|
Eris Lifesciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
5.2 % | 18.6 % | 8.7 % |
|
Financials
|
|||
|
5 yr Average ROE
|
18.31 % | 17.42 % | 17.74 % |
|
5yr average Equity Multiplier
|
1.21 | 1.99 | 1.76 |
|
5yr Average Asset Turnover Ratio
|
0.56 | 0.91 | 0.51 |
|
5yr Avg Net Profit Margin
|
27.33 % | 9.65 % | 22.76 % |
|
Price to Book
|
5.16 | 23.69 | 5.15 |
|
P/E
|
30.02 | 110.27 | 32.45 |
|
5yr Avg Cash Conversion Cycle
|
11.0 Days | -6.33 Days | -54.68 Days |
|
Inventory Days
|
49.21 Days | 68.19 Days | 27.48 Days |
|
Days Receivable
|
26.06 Days | 35.81 Days | 54.07 Days |
|
Days Payable
|
78.13 Days | 187.52 Days | 148.48 Days |
|
5yr Average Interest Coverage Ratio
|
181.67 | 142.38 | 66.44 |
|
5yr Avg ROCE
|
23.22 % | 23.84 % | 18.34 % |
|
5yr Avg Operating Profit Margin
|
32.54 % | 14.57 % | 34.43 % |
|
5 yr average Debt to Equity
|
0.0 | 0.0 | 0.46 |
|
5yr CAGR Net Profit
|
74.55 % | 4.4 % | -0.19 % |
|
5yr Average Return on Assets
|
15.17 % | 8.92 % | 12.4 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
63.92 % | 75.0 % | 53.92 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 16.92 % |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | 1.06 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
5.56 % | 4.44 % | 8.58 % |
|
Pfizer
|
Astrazeneca Pharma
|
Eris Lifesciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|